Aim of the collaboration is to develop mRNA platform technology, scale up and troubleshoot challenges in mRNA process optimization
The companies have initiated Phase 3 studies in patients with high-risk melanoma and non-small cell lung cancer
The demand in Africa for COVID-19 vaccines has declined
Wacker Biotech is a CDMO for the GMP-compliant production of active ingredients for the pharmaceutical industry
The initiation of the second clinical trial in the INTerpath program represents rapid expansion in research for additional tumor types for individualized neoantigen therapy, V940 (mRNA-4157)
2023 Nobel laureates discovered how pseudouridine could make mRNA suitable for vaccines
The companies plan to start a pivotal Phase 3 trial in the coming months
The discoveries by the two Nobel Laureates were critical for developing effective mRNA vaccines against COVID-19
The partnership is part of BioNTech’s strategy to develop novel prophylactic vaccines for the prevention of high-medical-need infectious diseases
CureVac is among many pharmaceutical companies looking to produce a novel seasonal influenza vaccine via mRNA technology
Subscribe To Our Newsletter & Stay Updated
